☆ 4.6 Review

Therapeutic use of psilocybin: Practical considerations for dosing and administration

FRONTIERS IN PSYCHIATRY (2022)

Related references

Note: Only part of the references are listed.

Article Pharmacology & Pharmacy

Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects

Anna M. Becker et al.

Summary: The study examined the interaction between escitalopram and psilocybin in the treatment of depression and anxiety. Escitalopram pretreatment was found to reduce certain negative effects of psilocybin, but further research is needed to fully understand the interactions between antidepressants and psilocybin in patients with psychiatric disorders.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2022)

Add to Collection

Review Clinical Neurology

Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression

Susan Ling et al.

Summary: Research on new rapid-acting antidepressants such as ketamine, esketamine, and psilocybin has shown promising potential in treating depression by modulating serotonin receptors and gene expression. The mechanisms underlying the therapeutic effects of these drugs are still being explored, with a focus on the modulation of serotonergic system and changes in neural circuitry.

CNS DRUGS (2022)

Add to Collection

Article Mycology

Diversity, biology, and history of psilocybin-containing fungi: Suggestions for research and technological development

R. C. Van Court et al.

Summary: Therapeutic use of psilocybin has gained attention in recent international research, highlighting the importance of understanding psilocybin-producing fungi for consumer safety.

FUNGAL BIOLOGY (2022)

Add to Collection

Review Psychology, Clinical

Why was early therapeutic research on psychedelic drugs abandoned?

Wayne Hall

Summary: This paper briefly describes research in the 1950s and 1960s in North America on the therapeutic use of LSD, and discusses the reasons that led to its abandonment. The factors include tighter regulation of pharmaceutical research, discrepancies between clinical trial results and the claims made by psychedelic advocates, and lack of interest from the pharmaceutical industry in funding clinical trials.

PSYCHOLOGICAL MEDICINE (2022)

Add to Collection

Review Anthropology

Towards psychedelic apprenticeship: Developing a gentle touch for the mediation and validation of psychedelic-induced insights and revelations

Christopher Timmermann et al.

Summary: A striking feature of psychedelics is their ability to increase attribution of truth and meaningfulness to specific contents and ideas experienced, which may persist long after psychedelic effects have subsided. However, this raises important considerations regarding the validation and mediation of knowledge gained during these experiences. The use of psychedelics is becoming increasingly mainstream, necessitating attention to ethical challenges and the use of ethical approaches and psychedelic apprenticeship as a solution.

TRANSCULTURAL PSYCHIATRY (2022)

Add to Collection

Article Biochemistry & Molecular Biology

5-HT2A SNPs Alter the Pharmacological Signaling of Potentially Therapeutic Psychedelics

Gavin P. Schmitz et al.

Summary: In this study, the researchers examined the effects of sequence variations in the 5-HT2AR gene on the signaling of four commonly used psychedelic drugs. They found that these genetic variations have statistically significant, but modest, effects on the efficacy and potency of the drugs. Importantly, these effects are specific to each drug.

ACS CHEMICAL NEUROSCIENCE (2022)

Add to Collection

Article Psychiatry

Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder A Randomized Clinical Trial

Michael P. Bogenschutz et al.

Summary: This study aimed to evaluate the effects of high-dose psilocybin on patients with AUD. The results showed that psilocybin combined with psychotherapy significantly decreased the percentage of heavy drinking days.

JAMA PSYCHIATRY (2022)

Add to Collection

Review Psychology, Clinical

Systematized Review of Psychotherapeutic Components of Psilocybin-Assisted Psychotherapy

David M. Horton et al.

Summary: This systematic review focused on investigating the structure and format of psilocybin-assisted psychotherapy (PAP), highlighting the counseling components of the treatment. The study identified commonalities in PAP clinical trials published within the past 25 years, while also noting key differences in the incorporation of psychotherapy. Further research is needed to understand the unique effects of psychotherapy in PAP.

AMERICAN JOURNAL OF PSYCHOTHERAPY (2021)

Add to Collection

Article Clinical Neurology

Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches

Albert Garcia-Romeu et al.

Summary: The study found that the subjective effects of psilocybin were not affected by body weight when administered either on a weight-adjusted basis or as a fixed dose. The convenience and lower cost of administering psilocybin as a fixed dose outweigh any potential advantages of weight-adjusted dosing.

JOURNAL OF PSYCHOPHARMACOLOGY (2021)

Add to Collection

Review Behavioral Sciences

Blood Brain-Derived Neurotrophic Factor (BDNF) and Major Depression: Do We Have a Translational Perspective?

Beatrice Arosio et al.

Summary: This article summarizes the neurotrophin hypothesis of depression and the relationship between blood BDNF concentration and MDD. Existing research suggests that changes in BDNF levels are associated with clinical manifestations of depression, but cannot yet be used as a biomarker in clinical practice.

FRONTIERS IN BEHAVIORAL NEUROSCIENCE (2021)

Add to Collection

Article Medicine, General & Internal

Trial of Psilocybin versus Escitalopram for Depression

Robin Carhart-Harris et al.

Summary: The study compared the efficacy of psilocybin and escitalopram in treating patients with major depressive disorder. While there was no significant difference in antidepressant effects between the two drugs at week 6, secondary outcomes generally favored psilocybin over escitalopram, though these results were not adjusted for multiple comparisons. Larger and longer trials are needed to further compare psilocybin with established antidepressants.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Psychiatry

Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder A Randomized Clinical Trial

Alan K. Davis et al.

Summary: The study showed that psilocybin therapy with psychological support is effective in treating MDD, building on previous findings in patients with cancer and depression, as well as in a nonrandomized study in patients with treatment-resistant depression.

JAMA PSYCHIATRY (2021)

Add to Collection

Review Psychiatry

Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics

Cato M. H. de Vos et al.

Summary: Clinical studies suggest that psychedelics induce rapid changes in neuroplasticity mechanisms, leading to alterations in gene and protein expression, increased neurotrophic factor levels, and enhanced dendritic complexity. Repeated administration of psychedelics can directly stimulate neurogenesis and elevate BDNF mRNA levels, indicating potential long-lasting effects on brain plasticity. Future research could focus on deciphering specific cellular mechanisms activated by different psychedelics to better understand their therapeutic potential.

FRONTIERS IN PSYCHIATRY (2021)

Add to Collection

Article Psychology, Multidisciplinary

Psychedelic-Assisted Psychotherapy Practices and Human Caring Science: Toward a Care-Informed Model of Treatment

Andrew D. Penn et al.

Summary: This article utilizes the nursing theory of human caring science to explore the essential human caring qualities in psychedelic therapy, creating a theoretical framework for future nursing-informed psychedelic psychotherapy research.

JOURNAL OF HUMANISTIC PSYCHOLOGY (2021)

Add to Collection

Article Clinical Neurology

Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin

Emmanuelle A. D. Schindler et al.

Summary: An exploratory study found that a single administration of psilocybin had a lasting therapeutic effect on migraine headaches, separate from its acute psychotropic effects. This highlights the importance of further investigating the clinical effects of select 5-HT2A receptor compounds in migraine and other neuropsychiatric conditions.

NEUROTHERAPEUTICS (2021)

Add to Collection

Article Pharmacology & Pharmacy

Exposure-Response Analysis to Assess the Concentration-QTc Relationship of Psilocybin/Psilocin

Elyes Dahmane et al.

Summary: The study assessed the potential proarrhythmic effect of psilocin and found a significant but shallow relationship between concentration-QTc interval. At clinical doses, the QTcF change was small and there was no accumulation of psilocin after monthly oral doses in trials.

CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2021)

Add to Collection

Article Substance Abuse

Recreational cannabis use impairs driving performance in the absence of acute intoxication

M. Kathryn Dahlgren et al.

DRUG AND ALCOHOL DEPENDENCE (2020)

Add to Collection

Article Clinical Neurology

Therapeutic mechanisms of psilocybin: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression

Lea J. Mertens et al.

JOURNAL OF PSYCHOPHARMACOLOGY (2020)

Add to Collection

Review Neurosciences

The Role of BDNF on Neural Plasticity in Depression

Yang Tao et al.

FRONTIERS IN CELLULAR NEUROSCIENCE (2020)

Add to Collection

Article Medicine, General & Internal

Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study

Brian T. Anderson et al.

ECLINICALMEDICINE (2020)

Add to Collection

Article Psychology, Clinical

Psilocybin-assisted therapy of major depressive disorder using Acceptance and Commitment Therapy as a therapeutic frame

Jordan Sloshower et al.

JOURNAL OF CONTEXTUAL BEHAVIORAL SCIENCE (2020)

Add to Collection

Article Neurosciences

Psilocybin with psychological support for treatment-resistant depression: six-month follow-up

R. L. Carhart-Harris et al.

PSYCHOPHARMACOLOGY (2018)

Add to Collection

Article Clinical Neurology

High dose psilocybin is associated with positive subjective effects in healthy volunteers

Christopher R. Nicholas et al.

JOURNAL OF PSYCHOPHARMACOLOGY (2018)

Add to Collection

Article Pharmacology & Pharmacy

Clinical Interpretations of Patient Experience in a Trial of Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder

Michael P. Bogenschutz et al.

FRONTIERS IN PHARMACOLOGY (2018)

Add to Collection

Article Clinical Neurology

Does getting high hurt? Characterization of cases of LSD and psilocybin-containing mushroom exposures to national poison centers between 2000 and 2016

James B. Leonard et al.

JOURNAL OF PSYCHOPHARMACOLOGY (2018)

Add to Collection

Review Clinical Neurology

Potential Therapeutic Effects of Psilocybin

Matthew W. Johnson et al.

NEUROTHERAPEUTICS (2017)

Add to Collection

Letter Pharmacology & Pharmacy

Role of psilocybin in the treatment of depression

Ananya Mahapatra et al.

THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY (2017)

Add to Collection

Article Pharmacology & Pharmacy

Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults

Randall T. Brown et al.

CLINICAL PHARMACOKINETICS (2017)

Add to Collection

Review Pharmacology & Pharmacy

Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance

Ricardo Jorge Dinis-Oliveira

DRUG METABOLISM REVIEWS (2017)

Add to Collection

Article Clinical Neurology

Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens

Anna Rickli et al.

EUROPEAN NEUROPSYCHOPHARMACOLOGY (2016)

Add to Collection

Review Clinical Neurology

Psychedelics in the treatment of unipolar mood disorders: a systematic review

James J. H. Rucker et al.

JOURNAL OF PSYCHOPHARMACOLOGY (2016)

Add to Collection

Article Clinical Neurology

Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial

Roland R. Griffiths et al.

JOURNAL OF PSYCHOPHARMACOLOGY (2016)

Add to Collection

Article Clinical Neurology

Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial

Stephen Ross et al.

JOURNAL OF PSYCHOPHARMACOLOGY (2016)

Add to Collection

Article Biodiversity Conservation

Traditional knowledge and use of wild mushrooms by Mixtecs or Nuu savi, the people of the rain, from Southeastern Mexico

Faustino Hernandez Santiago et al.

JOURNAL OF ETHNOBIOLOGY AND ETHNOMEDICINE (2016)

Add to Collection

Article Psychiatry

Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study

Robin L. Carhart-Harris et al.

LANCET PSYCHIATRY (2016)

Add to Collection

Article Clinical Neurology

Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study

Michael P. Bogenschutz et al.

JOURNAL OF PSYCHOPHARMACOLOGY (2015)

Add to Collection

Review Clinical Neurology

Hallucinogenic drugs in pre-Columbian Mesoamerican cultures

F. J. Carod-Artal

NEUROLOGIA (2015)

Add to Collection

Article Psychology, Clinical

Indoleamine Hallucinogens in Cluster Headache: Results of the Clusterbusters Medication Use Survey

Emmanuelle A. D. Schindler et al.

JOURNAL OF PSYCHOACTIVE DRUGS (2015)

Add to Collection

Review Clinical Neurology

Psilocybin - Summary of knowledge and new perspectives

Filip Tyls et al.

EUROPEAN NEUROPSYCHOPHARMACOLOGY (2014)

Add to Collection

Article Clinical Neurology

Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction

Matthew W. Johnson et al.

JOURNAL OF PSYCHOPHARMACOLOGY (2014)

Add to Collection

Article Neurosciences

Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes

Bruce E. Blough et al.

PSYCHOPHARMACOLOGY (2014)

Add to Collection

Article Multidisciplinary Sciences

Automated design of ligands to polypharmacological profiles

Jeremy Besnard et al.

NATURE (2012)

Add to Collection

Editorial Material Multidisciplinary Sciences

Hallucinogen actions on human brain revealed

Hyeong-Min Lee et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)

Add to Collection

Article Psychiatry

Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer

Charles S. Grob et al.

ARCHIVES OF GENERAL PSYCHIATRY (2011)

Add to Collection

Review Neurosciences

Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens

Adam L. Halberstadt et al.

NEUROPHARMACOLOGY (2011)

Add to Collection

Article Neurosciences

Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects

Roland R. Griffiths et al.

PSYCHOPHARMACOLOGY (2011)

Add to Collection

Article Neurosciences

OPINION The neurobiology of psychedelic drugs: implications for the treatment of mood disorders

Franz X. Vollenweider et al.

NATURE REVIEWS NEUROSCIENCE (2010)

Add to Collection

Review Clinical Neurology

Human hallucinogen research: guidelines for safety

M. W. Johnson et al.

JOURNAL OF PSYCHOPHARMACOLOGY (2008)

Add to Collection

Article Psychology, Clinical

Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder

Francisco A. Moreno et al.

JOURNAL OF CLINICAL PSYCHIATRY (2006)

Add to Collection

Article Clinical Neurology

Response of cluster headache to psilocybin and LSD

R. Andrew Sewell et al.

NEUROLOGY (2006)

Add to Collection

Article Neurosciences

Desensitization of 5-HT2A receptor function by chronic administration of selective serotonin reuptake inhibitors

M Yamauchi et al.

BRAIN RESEARCH (2006)

Add to Collection

Article Neurosciences

Attenuation of nicotine's discriminative stimulus effects in rats and its locomotor activity effects in mice by serotonergic 5-HT2A/2C receptor agonists

AM Batman et al.

PSYCHOPHARMACOLOGY (2005)

Add to Collection

Article Clinical Neurology

Decrease of the platelet 5-HT2A receptor function by long-term imipramine treatment in endogenous depression

E Gómez-Gil et al.

HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL (2004)

Add to Collection

Review Biochemistry & Molecular Biology

The pharmacology of psilocybin

T Passie et al.

ADDICTION BIOLOGY (2002)

Add to Collection

Article Psychiatry

The effect of paroxetine on 5-HT2A receptors in depression: An [F-18]setoperone PET imaging study

JH Meyer et al.

AMERICAN JOURNAL OF PSYCHIATRY (2001)

Add to Collection

© Peeref 2019-2024. All rights reserved.